Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

Contrast agent ‘not recommended’ in premature neonates

Premature neonates who are given oral Gastrografin immediately after birth do not pass meconium more quickly than others, study findings suggest.

10 Dec 2012

New hope for leukemia patients

Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania

10 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Sanofi announced today new Phase II data showing that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), a hematologic malignancy with unmet medical needs.

10 Dec 2012

Anti-seizure drug benefits women with severe morning sickness

Good news may be on the horizon for Kate Middleton, Duchess of Cambridge, and other women stricken with severe nausea and vomiting during pregnancy, thanks to the work of a University at Buffalo professor who is conducting research on a drug that is showing success treating pregnant women with this condition.

8 Dec 2012

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Results from the first large, global Phase III study of Halaven (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer were presented today during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

7 Dec 2012

RedHill Biopharma completes $6.5M private placement

RedHill Biopharma Ltd., an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical stage, patent-protected, new formulations and combinations of existing drugs, reported the completion of a private placement in a total amount of approximately $6.5 million.

6 Dec 2012

Synthetic marijuana linked to 11,406 of 4.9M drug-related ED visits in 2010

Street forms of synthetic cannabinoids - so-called "synthetic marijuana" - were linked to 11,406 of the 4.9 million drug-related emergency department (ED) visits in 2010, according to a new report by the Substance Abuse and Mental Health Services Administration (SAMHSA).

6 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Smokers more likely to report hangover symptoms after heavy drinking

People who like to smoke when they drink may be at greater risk of suffering a hangover the next morning, according to a study in the January 2013 issue of the Journal of Studies on Alcohol and Drugs.

5 Dec 2012

Study identifies factors that can predict postpartum pelvic girdle pain in working women

A new study of working women has identified factors during pregnancy and postpartum that can predict pain in the joints that comprise the pelvic girdle. While 90 percent of working women in the Netherlands return to work after the birth of their first child, health issues during the postpartum period often require sick leave. Chief among these health issues is pelvic girdle pain (PGP).

5 Dec 2012

Holiday stress and cold temperatures could lead to heart attacks if left unchecked

Amid the frenzy of decorating, planning and shopping for the holidays, health may take a backseat. However, the stress brought on by these activities plus cold temperatures could lead to heart attacks or heart-related complications if left unchecked.

1 Dec 2012

Pressure Right effectively reduces postdischarge nausea and vomiting

In its December 2012 issue, the Outpatient Surgery Magazine's product news section introduces Pressure Right, the longer-acting perioperative, (Rx) antiemetic prophylaxis medical device to its readers.

30 Nov 2012

Sucampo receives supplement approval from FDA for AMITIZA

Sucampo Pharmaceuticals, Inc. today announced that the Company received a supplement approval from the U.S. Food and Drug Administration (FDA) that removes pregnancy "warnings and precautions" and clarifies information regarding the use of AMITIZA (lubiprostone) by pregnant and/or nursing women. In addition, the FDA expanded the labeling text of the Mechanism of Action section in the prescribing information for AMITIZA.

30 Nov 2012

Eisai announces FDA acceptance of AcipHex NDA for priority review

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for AcipHex Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of Gastroesophageal Reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age.

30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

30 Nov 2012

Nausea News and Research

Further Reading

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Contrast agent ‘not recommended’ in premature neonates

New hope for leukemia patients

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Ibrutinib may effectively combat chronic lymphocytic leukemia

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Anti-seizure drug benefits women with severe morning sickness

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

RedHill Biopharma completes $6.5M private placement

Synthetic marijuana linked to 11,406 of 4.9M drug-related ED visits in 2010

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

Smokers more likely to report hangover symptoms after heavy drinking

Study identifies factors that can predict postpartum pelvic girdle pain in working women

Holiday stress and cold temperatures could lead to heart attacks if left unchecked

Pressure Right effectively reduces postdischarge nausea and vomiting

Sucampo receives supplement approval from FDA for AMITIZA

Eisai announces FDA acceptance of AcipHex NDA for priority review

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News